|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Tuberculosis Vaccines and Therapeutics
La Merie Publishing, May 2010, Pages: 38
The present Competitive Intelligence Report about Tuberculosis Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic small molecules against infection with Mycobacterium tuberculosis as of May 2010. Purchase of the PDF report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated incidence rate in sub-Saharan Africa is nearly twice that of the South-East Asia Region with over 350 cases per 100 000 population. An estimated 1.3 million people died from TB in 2008. The highest number of deaths was in the South-East Asia Region, while the highest mortality per capita was in the Africa Region. Until 50 years ago, there were no medicines to cure TB. Now, strains that are resistant to a single drug have been documented in every country surveyed; what is more, strains of TB resistant to all major anti-TB drugs have emerged. Drug-resistant TB is caused by inconsistent or partial treatment. A particularly dangerous form of drug-resistant TB is multidrug-resistant TB (MDR-TB), which is defined as the disease caused by TB bacilli resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs.
Private-public partnerships have considerably contributed to establish a tuberculosis vaccine and drug pipeline. So far, there is no approved vaccine for tuberculosis. Now, several vaccines are in clinical development and further in preclinical stages. Small molecule therapeutics are also in clinical and preclinical development and significant research efforts are being undertaken to discover novel small molecule therapeutics with a mechanism of action different from currently used treatments.
The report includes a compilation of currently active projects in development of vaccines and small molecules targeting Mycobacterium tuberculosis for prophylaxis and treatment of tuberculosis.
In addition, the report lists company-specific R&D pipelines of Tuberculosis Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- Additional comments with a hyperlink leading to the source of information.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of life
Tuberculosis Therapeutics - Global Strategic Business Report
AIDS and Tuberculosis: A Deadly Liaison
Molecular Diagnostics - Technologies, Markets and Companies
Evolving Patterns and Unmet Needs in the TB Population in Developing and Developed Markets
Innovations and Opportunities in Therapeutic Vaccines: Technology Platforms, Key Players, and Early Pipeline Candidates
Nitric Oxide - Therapeutics, Markets and Companies
Veterinary Vaccines - Global Strategic Business Report
World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
Plant-derived Vaccines
|
|
|
|
